What does IDE892 — external clinical development expenses mean?

This metric represents the total third-party costs incurred specifically for the clinical advancement of the IDE892 therapeutic candidate. It encompasses expenditures related to contract research organizations, clinical trial site operations, and patient enrollment activities necessary to move the asset through the regulatory pipeline. Monitoring these costs provides insight into the capital intensity and progress of the company's specific oncology development programs.

IDEAYA Biosciences, Inc. IDYA IDE892 — External Clinical Development Expenses

Similar metrics at other companies

RAPPPreclinical Programs External Expenses — Research And Development Expense

$4.29M+32.1%

BEAMExternal Research And Development Expenses — Research And Development Expense

$30.08M-12.6%

DNLITherapeutics Segment — External research and development expense

$38.46M-8.4%

INVAExternal Services — Research And Development Expense

$2.61M-14.6%

DYNDYNE-251DM1 — Research And Development Expense

$37.75M+79.0%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

Other financials

Income statement

See full

Revenue$6.6M—

Operating income-$108.5M-28.6%

Net income-$98.5M-36.5%

EPS (diluted)-$1.11-35.4%

Balance sheet

See full

Cash & equivalents$157.5M+21.2%

Total debt$28.6M+10.1%

Total equity$937.3M-8.5%

Total assets$1.0B-6.4%

Cash flow

See full

Operating cash flow-$75.2M-24.6%

CapEx$967.0K-27.3%

Free cash flow-$76.1M-23.5%

Valuation

See full

Market cap$3.36B+104%

Enterprise value$3.23B+110%

P/S14.5×+9.9×

Profitability

See full

Operating margin-4,671.1%-5,434pp

Net margin-3,921.1%-4,562pp

FCF margin-3,592%-4,290pp

Returns & leverage

See full

Return on equity-14.3%-5.0pp

Debt / equity0×0.0×

Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept idya:ExternalClinicalDevelopmentExpenses.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s ide892 — external clinical development expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s IDE892 — external clinical development expenses?: IDEAYA Biosciences, Inc. (IDYA) reported IDE892 — external clinical development expenses of $2.18M in Q1 2026.
What does IDE892 — external clinical development expenses mean?: This metric represents the total third-party costs incurred specifically for the clinical advancement of the IDE892 therapeutic candidate. It encompasses expenditures related to contract research organizations, clinical trial site operations, and patient enrollment activities necessary to move the asset through the regulatory pipeline. Monitoring these costs provides insight into the capital intensity and progress of the company's specific oncology development programs.